  | Servais, S., Baron, F., LECHANTEUR, C., Seidel, L., BAUDOUX, E., BRIQUET, A., Selleslag, D., Maertens, J., Poire, X., Schroyens, W., Graux, C., De Becker, A., Zachee, P., Ory, A., Herman, J., Kerre, T., & Beguin, Y. (2023). Multipotent mesenchymal stromal cells as treatment for poor graft function after allogeneic hematopoietic cell transplantation: A multicenter prospective analysis. Frontiers in Immunology, 14. doi:10.3389/fimmu.2023.1106464  Peer Reviewed verified by ORBi |
 | GREGOIRE, C.* , LAYIOS, N.* , LAMBERMONT, B., LECHANTEUR, C., BRIQUET, A., Bettonville, V., BAUDOUX, E., THYS, M., Dardenne, N., Misset, B.* , & BEGUIN, Y.*. (04 July 2022). Bone Marrow-Derived Mesenchymal Stromal Cell Therapy in Severe COVID-19: Preliminary Results of a Phase I/II Clinical Trial. Frontiers in Immunology, 13, 932360. doi:10.3389/fimmu.2022.932360 Peer Reviewed verified by ORBi* These authors have contributed equally to this work. |
 | GREGOIRE, C., SERVAIS, S., WILLEMS, E., BAUDOUX, E., LECHANTEUR, C., BRIQUET, A., Bettonville, V., DETRY, O., ERPICUM, P., JOURET, F., LOUIS, E., BARON, F., & BEGUIN, Y. (April 2022). Immunothérapie cellulaire au CHU de Liège : avancées, défis et perspectives. Revue Médicale de Liège, 77 (4), 206-211. Editorial Reviewed verified by ORBi |
 | VANDERMEULEN, M., Mohamed-Wais, M., ERPICUM, P., DELBOUILLE, M.-H., LECHANTEUR, C., BRIQUET, A., MAGGIPINTO, G., Jouret, F., Beguin, Y., & Detry, O. (2022). Infusion of allogeneic mesenchymal stromal cells after liver transplantation: Five-year follow-up. Liver Transplantation, 28, 636-646. doi:10.1002/lt.26323 Peer reviewed |
 | VIEUJEAN, S., LOLY, J.-P., BOUTAFFALA, L., MEUNIER, P., REENAERS, C., BRIQUET, A., LECHANTEUR, C., BAUDOUX, E., BEGUIN, Y., & LOUIS, E. (2022). Mesenchymal Stem Cell Injection in Crohn's Disease Strictures: a phase I-II clinical study. Journal of Crohn's and Colitis, 16, 506-510. doi:10.1093/ecco-jcc/jjab154 Peer Reviewed verified by ORBi |
  | VIEUJEAN, S., LOLY, J.-P., BOUTAFFALA, L., MEUNIER, P., REENAERS, C., BRIQUET, A., LECHANTEUR, C., BAUDOUX, E., BEGUIN, Y., & LOUIS, E. (October 2021). Local Mesenchymal Stem Cells injection in Crohn’s disease strictures: a phase I-II, open-label clinical study [Poster presentation]. United European Gastroenterology. Peer reviewed |
 | VIEUJEAN, S., LOLY, J.-P., BOUTAFFALA, L., Pariente, B., REENAERS, C., BRIQUET, A., LECHANTEUR, C., BEGUIN, Y., & LOUIS, E. (July 2021). Local Mesenchymal Stem Cells injection in Crohn’s disease strictures: a phase I-II, open-label clinical study [Poster presentation]. 16th Congress of European Crohn's and Colitis Organisation - Inflammatory Bowel Diseases 2021 Virtual. Peer reviewed |
 | LECHANTEUR, C., BRIQUET, A., Bettonville, V., BAUDOUX, E., & BEGUIN, Y. (2021). MSC Manufacturing for Academic Clinical Trials: From a Clinical-Grade to a Full GMP-Compliant Process. Cells, 10, 1320. doi:10.3390/cells10061320 Peer Reviewed verified by ORBi |
 | VANDERMEULEN, M., ERPICUM, P., WEEKERS, L., BRIQUET, A., LECHANTEUR, C., Detry, O., Beguin, Y., & Jouret, F. (May 2020). Mesenchymal Stromal Cells in Solid Organ Transplantation. Transplantation, 104 (5), 923-936. doi:10.1097/TP.0000000000003077 Peer Reviewed verified by ORBi |
 | Grégoire, C., Ritacco, C., Hannon, M., SEIDEL, L., Delens, L., Belle, L., DUBOIS, S., Veriter, S., LECHANTEUR, C., BRIQUET, A., Servais, S., Ehx, G., Beguin, Y., & Baron, F. (2019). Comparison of Mesenchymal Stromal Cells From Different Origins for the Treatment of Graft-vs.-Host-Disease in a Humanized Mouse Model. Frontiers in Immunology, 10, 619. doi:10.3389/fimmu.2019.00619 Peer Reviewed verified by ORBi |
 | ERPICUM, P., WEEKERS, L., DETRY, O., BONVOISIN, C., DELBOUILLE, M.-H., GREGOIRE, C., BAUDOUX, E., BRIQUET, A., LECHANTEUR, C., MAGGIPINTO, G., SOMJA, J., Pottel, H., Baron, F., Jouret, F., & BEGUIN, Y. (2019). Infusion of third-party mesenchymal stromal cells after kidney transplantation: a phase I-II, open-label, clinical study. Kidney International, 95, 693-707. doi:10.1016/j.kint.2018.08.046 Peer Reviewed verified by ORBi |
 | GREGOIRE, C., BRIQUET, A., PIRENNE, C., LECHANTEUR, C., LOUIS, E.* , & BEGUIN, Y.*. (November 2018). Allogeneic mesenchymal stromal cells for refractory luminal Crohn's disease: A phase I-II study. Digestive and Liver Disease, 50 (11), 1251-1255. doi:10.1016/j.dld.2018.08.015 Peer Reviewed verified by ORBi* These authors have contributed equally to this work. |
 | DETRY, O., VANDERMEULEN, M., DELBOUILLE, M.-H., SOMJA, J., BLETARD, N., Briquet, A., LECHANTEUR, C., GIET, O., BAUDOUX, E., Hannon, M., Baron, F., & Beguin, Y. (July 2017). Infusion of mesenchymal stromal cells after deceased liver transplantation: A phase I-II, open-label, clinical study. Journal of Hepatology, 67 (1), 47-55. doi:10.1016/j.jhep.2017.03.001 Peer Reviewed verified by ORBi |
 | WEEKERS, L., ERPICUM, P., DETRY, O., BONVOISIN, C., DELBOUILLE, M.-H., LECHANTEUR, C., BRIQUET, A., BAUDOUX, E., JOURET, F., & BEGUIN, Y. (16 March 2017). Administration of Third-Party Mesenchymal Stromal Cells at the Time of Kidney Transplantation: Interim Safety Analysis at One-Year Follow-Up [Paper presentation]. 24th Annual Meeting, Bruxelles, Belgium. |
 | GREGOIRE, C., Louis, E., BRIQUET, A., LECHANTEUR, C., BAUDOUX, E., GIET, O., Beguin, Y., & BARON, F. (2017). The role of mesenchymal stromal cells in the treatment of ulcerative colitis and Crohn’s disease. In The Biology and Therapeutic Application of Mesenchymal Cells (pp. 730-753). Hoboken, United States: John Wiley & Sons, Inc. Peer reviewed |
 | DETRY, O., VANDERMEULEN, M., DELBOUILLE, M.-H., SOMJA, J., BLETARD, N., BRIQUET, A., LECHANTEUR, C., GIET, O., BAUDOUX, E., Hannon, M., Baron, F., & BEGUIN, Y. (January 2017). UNE INJECTION UNIQUE DE CELLULES STROMALES MESENCHYMATEUSES AU JOUR 3 APRES GREFFE HEPATIQUE EST INSUFFISANTE POUR INDUIRE UNE TOLERANCE OPERATIONNELLE. Transplant International, 30 (suppl 1), 8 (O12. Peer Reviewed verified by ORBi |
 | GREGOIRE, C., LECHANTEUR, C., BRIQUET, A., BAUDOUX, E., BARON, F., LOUIS, E., & BEGUIN, Y. (2017). Review article: mesenchymal stromal cell therapy for inflammatory bowel diseases. Alimentary Pharmacology and Therapeutics, 45, 205-221. doi:10.1111/apt.13864 Peer Reviewed verified by ORBi |
 | GREGOIRE, C., DETRY, O., Jouret, F., BRIQUET, A., LECHANTEUR, C., BAUDOUX, E., Beguin, Y., & GIET, O. (2017). The use of mesenchymal stromal cells in solid organ transplantation. In The Biology and Therapeutic Application of Mesenchymal Cells (pp. 825-835). Hoboken, United States: John Willey & Sons, Inc. Peer reviewed |
 | Erpicum, P., WEEKERS, L., DETRY, O., BONVOISIN, C., LECHANTEUR, C., BRIQUET, A., BAUDOUX, E., JOURET, F., & BEGUIN, Y. (28 April 2016). Administration of Third-Party Mesenchymal Stromal Cells at the Time of Kidney Transplantation: Interim Safety Analysis at One-Year Follow-Up [Paper presentation]. Annual Meeting of the BVN-SBN, Bruxelles, Belgium. |
 | Grégoire, C., Beguin, Y., Hannon, M., DUBOIS, S., BAUDOUX, E., BRIQUET, A., LECHANTEUR, C., Ehx, G., & Baron, F. (29 January 2016). Umbilical cord mesenchymal stromal cells are superior to bone marrow and adipose tissue-derived mesenchymal stromal cells for the treatment of xenogeneic graft-versus-host disease in mice [Poster presentation]. 31th General Meeting of the Belgian Hematological Society. |
 | SERVAIS, S., GREGOIRE, C., BARON, F., WILLEMS, E., BRIQUET, A., BAUDOUX, E., DELLOYE, O., GIET, O., LECHANTEUR, C., & BEGUIN, Y. (2016). Multipotent mesenchymal stromal cell therapy for steroid-refractory acute graft-versus-host disease after allogeneic stem cell transplantation. Belgian Journal of Hematology, 7, 229-235. Peer Reviewed verified by ORBi |
 | LECHANTEUR, C., BRIQUET, A., GIET, O., DELLOYE, O., BAUDOUX, E., & BEGUIN, Y. (2016). Clinical - scale expansion of mesenchymal stromal cells: a large banking experience. Journal of Translational Medicine, 14, 145-159. doi:10.1186/s12967-016-0892-y Peer Reviewed verified by ORBi |
 | WEEKERS, L., Erpicum, P., DETRY, O., BONVOISIN, C., BRIQUET, A., LECHANTEUR, C., BAUDOUX, E., JOURET, F., & BEGUIN, Y. (2016). administration of Third-Party Mesenchymal Stromal Cells at the Time of Kidney Transplantation: Interim Safety Analysis at One-Year Follow-Up. Transplant International, 29 (Suppl 2), 13 -p6. Peer Reviewed verified by ORBi |
 | WEEKERS, L., ERPICUM, P., DETRY, O., JOURET, F., LECHANTEUR, C., DELBOUILLE, M.-H., BRIQUET, A., BAUDOUX, E., & BEGUIN, Y. (November 2015). Third-party mesenchymal stem cell infusion in kidney transplant recipient: 6-month safety interim analysis. Transplant International, 28 (S4), 223-224/BO278. Peer Reviewed verified by ORBi |
 | DETRY, O., VANDERMEULEN, M., DELBOUILLE, M.-H., DE ROOVER, A., SOMJA, J., BLETARD, N., BRIQUET, A., LECHANTEUR, C., HONORE, P., & BEGUIN, Y. (November 2015). Infusion of third-party mesenchymal stem cells after liver transplantation: a phase-1, open-label, clinical study. Transplant International, 28 (S4), 10/O27. Peer Reviewed verified by ORBi |
 | DETRY, O., VANDERMEULEN, M., DELBOUILLE, M.-H., DE ROOVER, A., SOMJA, J., BLETARD, N., BRIQUET, A., LECHANTEUR, C., & BEGUIN, Y. (April 2015). Infusion of third-party mesenchymal stromal cells after liver transplantation: a phase 1, open-label, clinical study. Journal of Hepatology, 62 (S2), 311 (P0052. Peer Reviewed verified by ORBi |
 | DETRY, O., VANDERMEULEN, M., DELBOUILLE, M.-H., DE ROOVER, A., SOMJA, J., BLETARD, N., BRIQUET, A., LECHANTEUR, C., & BEGUIN, Y. (27 March 2015). Infusion of third-party mesenchymal stromal cells after liver transplantation: a phase 1, open-label, clinical study [Poster presentation]. 22nd Annual Meeting, Brussels, Belgium. |
 | DETRY, O., VANDERMEULEN, M., DELBOUILLE, M.-H., DE ROOVER, A., SOMJA, J., BLETARD, N., BRIQUET, A., LECHANTEUR, C., & BEGUIN, Y. (March 2015). Infusion of third-party mesenchymal stream cells after liver transplantation: a phase-1, open-label, clinical study. Acta Gastro-Enterologica Belgica, 78 (1), 29. Peer Reviewed verified by ORBi |
 | Rowart, P., ERPICUM, P., Detry, O., WEEKERS, L., Grégoire, C., LECHANTEUR, C., BRIQUET, A., Beguin, Y., Krzesinski, J.-M., & Jouret, F. (2015). Mesenchymal Stromal Cell Therapy in Ischemia/Reperfusion Injury. Journal of Immunology Research, 602597. doi:10.1155/2015/602597 Peer Reviewed verified by ORBi |
 | DETRY, O., JOURET, F., VANDERMEULEN, M., ERPICUM, P., Delens, L., GREGOIRE, C., BRIQUET, A., WEEKERS, L., BAUDOUX, E., LECHANTEUR, C., & BEGUIN, Y. (December 2014). Cellules stromales mésenchymateuses et transplantation d'organes. Revue Médicale de Liège, 69, 53-56. Peer reviewed |
 | Baron, F., Humblet-Baron, S., Ehx, G., SERVAIS, S., HANNON, M., Belle, L., LECHANTEUR, C., BRIQUET, A., GIET, O., BAUDOUX, E., WILLEMS, E., & Beguin, Y. (2014). Thinking out of the box - New approaches to controlling GVHD. Current Hematologic Malignancy Reports, 9, 73-84. doi:10.1007/s11899-013-0187-9 Peer Reviewed verified by ORBi |
 | BRIQUET, A., GREGOIRE, C., Comblain, F., Servais, L., Zeddou, M., LECHANTEUR, C., & Beguin, Y. (2014). Human bone marrow, umbilical cord or liver mesenchymal stromal cells fail to improve liver function in a model of CCl4-induced liver damage in NOD/SCID/IL-2Ry(null) mice. Cytotherapy, 16, 1511-1518. doi:10.1016/j.jcyt.2014.07.003 Peer Reviewed verified by ORBi |
 | Binsfeld, M., Beguin, Y., Belle, L., Otjacques, E., HANNON, M., BRIQUET, A., Heusschen, R., Drion, P., Zilberberg, J., Bogen, B., Baron, F., & CAERS, J. (2014). Establishment of a murine graft-versus-myeloma model using allogeneic stem cell transplantation. PLoS ONE, 113764. doi:10.1371/journal.pone.0113764 Peer Reviewed verified by ORBi |
 | Erpicum, P., DETRY, O., WEEKERS, L., BONVOISIN, C., LECHANTEUR, C., BRIQUET, A., Beguin, Y., Krzesinski, J.-M., & Jouret, F. (2014). Mesenchymal stromal cell therapy in conditions of renal ischaemia/reperfusion. Nephrology Dialysis Transplantation, 29, 1487-1493. doi:10.1093/ndt/gft538 Peer Reviewed verified by ORBi |
 | LECHANTEUR, C., Baila, S., Janssen, M. E., GIET, O., BRIQUET, A., BAUDOUX, E., & Beguin, Y. (2014). Large-Scale Clinical Expansion of Mesenchymal Stem Cells in the GMP-Compliant, Closed Automated Quantum® Cell Expansion System: Comparison with Expansion in Traditional T-Flasks. Journal of Stem Cell Research and Therapy, 4 (8), 1000222. doi:10.4172/2157- 7633.1000222 Peer Reviewed verified by ORBi |
 | VANDERMEULEN, M., GREGOIRE, C., BRIQUET, A., LECHANTEUR, C., BEGUIN, Y., & DETRY, O. (2014). Rationale for the potential use of mesenchymal stromal cells in liver transplantation. World Journal of Gastroenterology, 20 (44), 16418-32. doi:10.3748/wjg.v20.i44.16418 Peer Reviewed verified by ORBi |
 | Binsfeld, M., BEGUIN, Y., Belle, L., Otjacques, E., HANNON, M., BRIQUET, A., Drion, P., Bogen, B., Baron, F., & CAERS, J. (2014). Establishment of a murine graft-versus-myeloma model using allogeneic stem cell transplantation. Belgian Journal of Hematology. |
| Binsfeld, M., BEGUIN, Y., Belle, L., Otjacques, E., HANNON, M., BRIQUET, A., Drion, P., Bogen, B., BARON, F., & CAERS, J. (April 2013). Establishment of a murine graft-versus-myeloma model using allogeneic stem cell transplantation [Poster presentation]. 3rd International Conference "Cancer Immunotherapy and Immunomonitoring (CITIM)", Cracovie, Poland. |
 | Bruck, F.* , Belle, L.* , LECHANTEUR, C., de Leval, L., Hannon, M., DUBOIS, S., CASTERMANS, E., Humblet-Baron, S., Rahmouni, S., Beguin, Y., BRIQUET, A.* , & Baron, F.*. (March 2013). Impact of bone marrow-derived mesenchymal stromal cells on experimental xenogeneic graft-versus-host disease. Cytotherapy, 15 (3), 267-279. doi:10.1016/j.jcyt.2012.09.003 Peer Reviewed verified by ORBi* These authors have contributed equally to this work. |
 | Belle, L., BINSFELD, M., DUBOIS, S., Hannon, M., Caers, J., BRIQUET, A., MENTEN, C., BEGUIN, Y., Humblet-Baron, S., & Baron, F. (February 2013). Prevention of murine sclerodermatous chronic graft-versus-host disease by Rapamycin. Biology of Blood and Marrow Transplantation, 19, 317. Peer Reviewed verified by ORBi |
 | Belle, L., Binsfeld, M., HANNON, M., CAERS, J., BRIQUET, A., MENTEN, C., BEGUIN, Y., Humblet-Baron, S., & Baron, F. (2013). Combination of Regulatory T Cells Injection with Rapamycin for Treatment of Chronic Graft-versus-Host Disease. Belgian Journal of Hematology. Peer Reviewed verified by ORBi |
Belle, L., Binsfeld, M., Dubois, S., Hannon, M., CAERS, J., BRIQUET, A., MENTEN, C., BEGUIN, Y., Humblet-Baron, S., & BARON, F. (2013). Prevention of murine sclerodermatous chronic graft-versus-host disease by Rapamycin [Poster presentation]. BMT Tandem Meetings (ASBMT), Salt Lake City, United States. |
 | BRIQUET, A., HALLEUX, A., LECHANTEUR, C., & BEGUIN, Y. (2013). Neuropeptides to replace serum in cryopreservation of mesenchymal stromal cells ? Cytotherapy, 15, 1385-1394. doi:10.1016/j.jcyt.2013.06.012 Peer Reviewed verified by ORBi |
 | Belle, L., Binsfeld, M., Hannon, M., CAERS, J., BRIQUET, A., MENTEN, C., Beguin, Y., Humblet-Baron, S., & BARON, F. (2013). Combination of Regulatory T Cells Injection with Rapamycin for Treatment of Chronic Graft-versus-Host Disease [Paper presentation]. 28th General Meeting of the Belgian Hematological Society. |
 | Belle, L., BINSFELD, M., Dubois, S., Hannon, M., CAERS, J., BRIQUET, A., MENTEN, C., Beguin, Y., Humbelt-Baron, S., & BARON, F. (April 2012). Rapamycin prevents experimental sclerodermatous chronic graft-versus-host disease in mice. Bone Marrow Transplantation, 47 Suppl 1. Peer Reviewed verified by ORBi |
BRIQUET, A., Grégoire, C., Beguin, Y., & Gothot, A. (April 2012). Inhibition of the Jagged-1/Notch pathway increases the hematopoiesis-supportive activity of mesenchymal stem cells [Paper presentation]. ESH-EHA Workshop Anti-Inflammatory & Immune Modulatory Properties of MSCs, Mandelieu, France. |
 | Belle, L., Binsfeld, M., DUBOIS, S., Hannon, M., CAERS, J., Briquet, A., MENTEN, C., Beguin, Y., Humblet-Baron, S., & Baron, F. (2012). Rapamycin prevents experimental sclerodermatous chronic graft-versus-host disease in mice [Paper presentation]. 38th EBMT Annual Meeting. |
 | Bruck, F., de Leval, L., Belle, L., LECHANTEUR, C., Hannon, M., BRIQUET, A., Dubois, S., CASTERMANS, E., Humblet-Baron, S., Rahmouni, S., BEGUIN, Y., & BARON, F. (2012). Bone marrow-derived mesenchymal stromal cells failed to prevent experimental xenogeneic graft-versus-host disease [Poster presentation]. Belgian Hematological Society General Annual Meeting. |
 | Belle, L., Bruck, F., FOGUENNE, J., GOTHOT, A., BEGUIN, Y., BARON, F., & BRIQUET, A. (2012). Imatinib and Nilotinib do not prevent adhesion and migration of human CD34+ in vitro and in immunodeficient mice [Poster presentation]. Belgian Hematological Society Annual Meeting. |
 | Belle, L., Bruck, F., FOGUENNE, J., GOTHOT, A., BEGUIN, Y., Baron, F., & Briquet, A. (2012). Imatinib and Nilotinib Inhibit Hematopoietic Progenitor Cell Growth, but Do Not Prevent Adhesion, Migration and Engraftment of Human Cord Blood CD34+ Cells. PLoS ONE, 7 (12), 52564. doi:10.1371/journal.pone.0052564 Peer Reviewed verified by ORBi |
 | Belle, L., Bruck, F., FOGUENNE, J., Gothot, A., Beguin, Y., Baron, F., & BRIQUET, A. (2012). Imatinib and Nilotinib do not prevent adhesion and migration of human CD34+ in vitro and in immunodeficient mice. Belgian Journal of Hematology. Peer Reviewed verified by ORBi |
 | Belle, L., Binsfeld, M., DUBOIS, S., Hannon, M., CAERS, J., BRIQUET, A., MENTEN, C., Beguin, Y., Humblet-Baron, S., & Baron, F. (2012). Rapamycin Prevents Experimental Sclerodermatous Chronic Graft-versus-Host Disease in mice [Paper presentation]. 27th General Meeting of the Belgian Hematological Society. |
 | Bruck, F., Baron, F., DUBOIS, S., BRIQUET, A., Hannon, M., Belle, L., MENTEN, C., Beguin, Y., & Humblet-Baron, S. (February 2011). Rapamycin Delays Xenogeneic Acute Graft Versus Host Disease (aGVHD) in Nod/Scid/Il2RγNull (NSG) Mice: Impact of Regulatory T Cells [Poster presentation]. ASBMT meeting 2011. doi:10.1016/j.bbmt.2010.12.535 |
 | Bruck, F., BARON, F., Dubois, S., BRIQUET, A., Hannon, M., Belle, L., MENTEN, C., BEGUIN, Y., & Humblet-Baron, S. (2011). The mTor inhibitor rapamycin delays xenogeneic acute graft versus host disease (aGVHD) in NOD/SCID/IL2rgnull mice (NSG): impact of regulatory T cells [Poster presentation]. Belgian Hematological Society Annual General Meeting. |
 | Belle, L., Baron, F., Bruck, F., Hannon, M., Servais, S., Beguin, Y., & BRIQUET, A. (2011). Despite Inhibitory Effects on Normal Hematopoiesis in Vitro, Imatinib and Nilotinib do not Prevent Engraftment of Human CD34+ HSCs in immunodeficient NSG Mice [Poster presentation]. 26th General Meeting of the Belgian Hematological Society. |
BRIQUET, A., Grégoire, C., Beguin, Y., & Gothot, A. (January 2011). Inhibition of the Jagged-1/Notch pathway increases the hematopoiesis-supportive activity of mesenchymal stem cells [Poster presentation]. 26th General Meeting of the Belgian Hematological Society, Liège, Belgium. |
 | Bruck, F., BARON, F., Dubois, S., BRIQUET, A., Hannon, M., Belle, L., MENTEN, C., BEGUIN, Y., & Humblet-Baron, S. (2011). Rapamycin delays xenogeneic acute graft-versus-host disease (aGvHD) in NOD/SCID/IL2Rg NULL (NSG) mice: impact of regulatory T cells [Poster presentation]. ASBMT 2011. |
 | Belle, L., Baron, F., Bruck, F., Hannon, M., SERVAIS, S., Beguin, Y., & BRIQUET, A. (2011). Despite inhibitory effects on normal hematopoiesis in vitro, Imatinib and Nilotinib do not prevent engraftment of human CD34+ HSCs in immunodeficient NSG mice. Belgian Journal of Hematology. Peer Reviewed verified by ORBi |
| Verwilghen, D., Briquet, A., Gothot, A., & Serteyn, D. (07 May 2010). STEM CELL IN THE TREATMENT OF TENDONITIS IN EQUINE PATIENTS [Poster presentation]. Meeting of the FNRS Contact-Group "Stem cells" 2010, Liege, Belgium. |
 | Briquet, A., Dubois, S., Bekaert, S., Dolhet, M., Beguin, Y., & Gothot, A. (2010). Prolonged ex vivo culture of human bone marrow mesenchymal stem cells influences their supportive activity toward NOD/SCID -repopulating cells and committed progenitor cells of B lymphoid and myeloid lineages. Haematologica, 95 (1), 47-56. doi:10.3324/haematol.2009.008524 Peer Reviewed verified by ORBi |
 | Zeddou, M., Briquet, A., Relic, B., Josse, C., Malaise, M., Gothot, A., Lechanteur, C., & Beguin, Y. (2010). The umbilical cord matrix is a better source of mesenchymal stem cells (MSC) than the umbilical cord blood. Cell Biology International, 34 (7), 693-701. doi:10.1042/CBI20090414 Peer Reviewed verified by ORBi |
 | Briquet, A. (2009). Etude des propriétés hémato-supportives in vitro des cellules souches mésenchymateuses [Doctoral thesis, ULiège - Université de Liège]. ORBi-University of Liège. https://orbi.uliege.be/handle/2268/11005 |
 | Briquet, A., Dolhet, M., Beguin, Y., & Gothot, A. (2009). Inhibition of the Jagged-1/Notch pathway increases the hematopoiesis-supportive activity of mesenchymal stem cells. Experimental Hematology, 37 (9), 77. Peer reviewed |
 | Belaid-Choucair, Z., Lepelletier, Y., Poncin, G., Thiry, A., Humblet, C., Maachi, M., Beaulieu, A., Schneider, E., Briquet, A., Mineur, P., Lambert, C., Mendes-Da-Cruz, D., Ahui, M. L., Asnafi, V., Dy, M., Boniver, J., Nusgens, B., Hermine, O., & Defresne, M.-P. (2008). Human bone marrow adipocytes block granulopoiesis through neuropilin-1-induced granulocyte colony-stimulating factor inhibition. Stem Cells, 26 (6), 1556-64. doi:10.1634/stemcells.2008-0068 Peer Reviewed verified by ORBi |
 | Chatel, G., Ganeff, C., Boussif, N., Delacroix, L., Briquet, A., Nolens, G., & Winkler, R. (15 December 2007). Hedgehog signaling pathway is inactive in colorectal cancer cell lines. International Journal of Cancer, 121 (12), 2622-2627. doi:10.1002/ijc.22998 Peer Reviewed verified by ORBi |
 | Briquet, A., Beguin, Y., & Gothot, A. (September 2007). The hematopoiesis-supporting activity of mesenchymal stem cells increases with the number of passages. Experimental Hematology, 35 (9, Suppl. 2), 125-125. Peer reviewed |
 | Briquet, A., Dolhet, M., Demeuse, J., BEGUIN, Y., & GOTHOT, A. (August 2007). Study of contribution of signalling pathways Notch, Wnt, Shh and BMP in mesenchymal stem cell prohaematopoietic activity. Acta Clinica Belgica, 62 (4), 256. Peer Reviewed verified by ORBi |
 | Briquet, A. (2005). Definition of quality standards applicable to the purification and the expansion of mesenchymal stem cells for their use in haematopoietic, immunosuppressive and regenerative cellular therapy [Specialised master, ULiège - Université de Liège]. ORBi-University of Liège. https://orbi.uliege.be/handle/2268/11058 |
Briquet, A. (2004). Caractérisation des mécanismes inhibiteurs de la voie de signalisation Hedgehog dans les cancers du côlon [Master’s dissertation, ULiège - Université de Liège]. ORBi-University of Liège. https://orbi.uliege.be/handle/2268/11054 |